Emerging Strategies for the Management of Resistant Hypertension
This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC
Delve into emerging therapies for resistant hypertension in this symposium highlights video. Hear from a multidisciplinary panel of experts discussing the current state of evaluation, diagnosis, and management of resistant hypertension, along with the challenges faced by clinicians. A patient case study and panel discussion provide practical advice for improving patient outcomes within the evolving treatment landscape for a robust and engaging learning experience.
Sripal Bangalore, MD, MHA
Professor, Department of Medicine
Director, Invasive and Interventional Cardiology, Interventional Director, Adult ECMO and MCS Program
New York University Grossman School of Medicine
New York, NY
John Flack, MD, MPH
Professor and Chair, Sergio Rabinovich Endowed Chair of Internal Medicine
Hypertension Section Chief, Department of Medicine
Southern Illinois University
Sandra Taler, MD
Professor of Medicine
Division of Nephrology and Hypertension, Dept. of Internal Medicine
October 28, 2022
October 28, 2023
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires all speakers to disclose that a product is not labeled for the use under discussion.
This activity is intended for cardiologists, nephrologists, neurologists, endocrinologists, clinical pharmacists, and other clinicians who evaluate, diagnose, or manage patients with resistant hypertension.
Resistant hypertension (RH) is challenging to treat and is associated with a poor prognosis despite the availability of numerous therapeutic options and detailed guideline recommendations. To address this unmet need, emerging therapies with novel mechanisms of action are being studied and/or have demonstrated their effectiveness in treating RH, with the potential to substantially change future treatment paradigms. To fully realize the potential benefits of these emerging therapies, experts in hypertension from various specialties treating patients with or at risk for RH must understand the challenges that underlie current treatment of RH to formulate effective multispecialty solutions to improve practice now and in the future.
Upon completion of this activity, participants will be able to:
- Describe guideline-endorsed strategies for the treatment of resistant hypertension in clinical practice.
- Discuss clinical data and ongoing studies regarding potential practice-changing emerging pharmacologic therapies directed at treating resistant hypertension.
METHOD OF PARTICIPATION
This activity will take approximately 1 hour to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Ty Jackson at email@example.com
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been approved for 1.0 contact hour.
Type of Activity: Knowledge
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Sripal Bangalore, MD (Faculty)
Advisory Board: Amgen, Merck, Pfizer
John Flack, MD, MPH (Faculty)
Consulting Agreements: Amgen, FibroGen, Glaxo Smith Kline, Janssen, Merck
Sources of Funding for Research: Indorsia, ReCor Medical, Quantam Genomics, Vascular Dynamics
Other: Teva (Expert Witness)
Sandra Taler, MD (Faculty) has no financial relationships to disclose.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Empagliflozin, dapagliflozin, canagliflozin, sacubitril/valsartan combination, firibastat, and aprocitentan are not approved for the treatment of resistant hypertension. No device-based therapies are approved for the treatment of resistant hypertension.
STAFF AND REVIEWER DISCLOSURES
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
© 2022 Academy for Continued Healthcare Learning
Academy for Continued Healthcare Learning
230 West Monroe Street, Suite 2300
Chicago, Illinois 60606
Ph (877) 444-8435